Assessing Chest Pain Using Point-of-Care High-Sensitivity Troponin I in the Emergency Department
- Conditions
- ACS (Acute Coronary Syndrome)
- Registration Number
- NCT06899776
- Lead Sponsor
- Wake Forest University Health Sciences
- Brief Summary
The goal of this proposal is to improve the quality and value of care for patients with acute chest pain by investigating the potential impact of point-of-care (POC) high sensitivity cardiac troponin (hs-cTn) testing in the Emergency Department (ED) and exploring how best to integrate POC hs-cTnl into ED risk stratification workflows. The study hypothesizes that the Abbott i-STAT POC hs-cTnI assay will decrease time-to-result (TTR) and ED length of stay (LOS), while increasing ED revenue for patients with acute chest pain compared to a strategy of central laboratory hs-cTnI testing.
- Detailed Description
Use of point-of-care (POC) testing in the Emergency Department (ED) has been previously established as a method to reduce the time-to-disposition-decision (TTD) making for emergency physicians, which in-turn can reduce ED length of stay (LOS) and time-to-treatment (TTT) of time sensitive conditions, such as myocardial infarctions (MIs). Recently, new POC high sensitivity cardiac troponin I (hs-cTnI) assays have been developed which offer similar diagnostic performance to traditional central lab hs-cTnI testing. However, data examining POC hs-cTnI measurement in U.S. ED settings are limited. In particular, studies have yet to evaluate the potential impact of POC hs-cTnI implementation on time to troponin result (TTR), time-to-last-troponin-result (TTLT), time-to-disposition-decision (TTD), time-to-treatment (TTT), and ED LOS. In addition, limited data exists on how best to implement POC hs-cTnI into ED clinical practice, such as whether POC hs-cTnI measures should be paired with a risk score or incorporated into an accelerated diagnostic protocol.
This record is a prospective multisite observational cohort study of 600 adult ED patients with symptoms suggestive of acute coronary syndrome and without ST-segment elevation myocardial infarction (STEMI) across 3 EDs. Participants, accrued under a waiver of informed consent, will undergo a standard-of-care evaluation for possible acute coronary syndrome (ACS) in the ED including blood testing for hs-cTnI (Beckman Coulter) completed in a central laboratory. During the study period all ED patients with chest pain will have an extra lithium heparin blood sample obtained for each troponin test ordered and collected in the ED (typically 2, but this may range from 1-3 troponin measures), which will be used for immediate hs-cTnI measurement by research personnel using an Abbott i-STAT Alinity. Clinicians will be blinded to the POC hs-cTnI results and will base clinical decisions on central laboratory hs-cTn measures. Blood draw times, result times for point-of-care (POC) and central laboratory measures, patient ED arrival, patient ED bedded, ED disposition decision times, and ED discharge times will be recorded on all patients. Following each POC hs-cTnI measurement the treating attending physician will be surveyed regarding whether a negative or positive POC result would change ED disposition or treatment including time stamps to determine estimated TTD, ED LOS and TTT for the POC hs-cTnI measurement strategy. Data from these surveys will be compared to actual TTD, ED LOS and treatment times based on the central laboratory hs-cTnI measurement strategy.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 600
- Age greater than or equal to18 years
- Symptoms suggestive of acute coronary syndrome:
- Acute chest, epigastric, neck, jaw or arm pain or discomfort or pressure without apparent non-cardiac source
- Shortness of breath, nausea, vomiting, fatigue/malaise, or
- Other equivalent discomfort suggestive of an myocardial infarction (MI)
- Electrocardiogram (ECG) ordered as part of standard of care
- At least one troponin collected as standard of care
- Study specific blood sample collected within ± 5 minutes of clinical draw
- ST-segment elevation myocardial infarction (STEMI) Activation
- Unstable vitals signs: symptomatic hypotension at the time of enrollment (systolic < 90 mm Hg), tachycardia (HR>120), bradycardia (HR<40), and hypoxemia (<90% pulse-oximetry on room air or normal home oxygen flow rate)
- Central laboratory hs-cTn testing resulted or in process (>5 minutes) prior to study accrual
- Prior enrollment
- Terminal diagnosis with life expectancy less than 6 months
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time-to-result (TTR) of hs-cTnI Index visit to Hour 24 Defined as the time from blood collection to result time of the hs-cTnI assay, as recorded by research staff for the Abbott i-STAT POC device and by the electronic health record for central lab Beckman Coulter Access 2 hs-cTnI measures. TTR will be collected for each troponin test ordered and collected in the Emergency Department (typically two tests per patient).
- Secondary Outcome Measures
Name Time Method Time-to-treatment (TTT) Index visit to Hour 24 Defined by the time from the patient being bedded in the ED to the provider's decision to initiate treatment for patients with a Type 1 Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) diagnosis (e.g., heparin drip).
Time-to-last-troponin-result (TTLT) Index visit to Hour 24 Defined as the time from ED arrival to the result time of the last hs-cTnI measure in the ED (by the POC and central lab strategies).
Time-to-disposition decision (TTD) Index visit to Hour 24 Defined as the time from the patient being bedded in the ED to provider decision on disposition (discharge vs admission).
ED length of stay (LOS) Index visit to Hour 72 Defined as the time from ED arrival to disposition (discharged, admitted, observation unit, left against medical advice, transfer, etc.).
ED Revenue amount Index visit to Month 6 Calculate the associated ED revenue generated based on an average of $550 in revenue per bed-hour.
Number of Myocardial Infarctions (MI) Baseline and Week 1 Number of Myocardial Infarctions (MI)
Number of Cardiac Deaths Baseline and Day 30 Number of Cardiac Deaths
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (3)
Wake Forest School of Medicine
🇺🇸Winston-Salem, North Carolina, United States
Carolinas Medical Center
🇺🇸Charlotte, North Carolina, United States
High Point Medical Center
🇺🇸High Point, North Carolina, United States